Everolimus-Eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy: the CART (Cardiac Allograft Reparative Therapy) Prospective Multicenter Pilot Study

详细信息    查看全文

• 作者：Michele Pighi ; Fabrizio Tomai…
• 关键词：Everolimus ; eluting bioresorbable vascular scaffold ; Cardiac allograft vasculopathy ; Heart transplant
• 刊名：Journal of Cardiovascular Translational Research
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：9
• 期：1
• 页码：40-48
• 全文大小：490 KB
• 参考文献：1.Taylor, D. O., Edwards, L. B., Aurora, P., Christie, J. D., Dobbels, F., Kirk, R., et al. (2008). Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult heart transplant report—2008. The Journal of Heart and Lung Transplantation, 27(9), 943–56.CrossRef PubMed
  2.Colvin-Adams, M., Harcourt, N., & Duprez, D. (2013). Endothelial dysfunction and cardiac allograft vasculopathy. Journal of Cardiovascular Translational Research, 6(2), 263–77.CrossRef PubMed
  3.van den Hoogen, P., Huibers, M. M. H., Sluijter, J. P. G., & de Weger, R. A. (2015). Cardiac allograft vasculopathy: a donor or recipient induced pathology? Journal of Cardiovascular Translational Research, 8(2), 106–16. Springer US.PubMedCentral CrossRef PubMed
  4.Mehra, M. R., Crespo-Leiro, M. G., Dipchand, A., Ensminger, S. M., Hiemann, N. E., Kobashigawa, J. A., et al. (2010). International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy—2010. HEALUN, 29(7), 717–27. Elsevier.
  5.Kobashigawa, J. A., Tobis, J. M., Starling, R. C., Tuzcu, E. M., Smith, A. L., Valantine, H. A., et al. (2005). Multicenter intravascular ultrasound validation study among heart transplant recipients. Journal of the American College of Cardiology, 45(9), 1532–7.CrossRef PubMed
  6.Tomai, F., Adorisio, R., De Luca, L., Pilati, M., Petrolini, A., Ghini, A. S., et al. (2014). Coronary plaque composition assessed by intravascular ultrasound virtual histology: association with long-term clinical outcomes after heart transplantation in young adult recipients. Catheterization and Cardiovascular Interventions, 83(1), 70–7.CrossRef PubMed
  7.Tomai, F., De Luca, L., Petrolini, A., Di Vito, L., Ghini, A. S., Corvo, P. (2015). Optical coherence tomography for characterization of cardiac allograft vasculopathy in late survivors of pediatric heart transplantation. The Journal of Heart and Lung Transplantation. 0(0) Elsevier.
  8.Hou, J., Lv, H., Jia, H., Zhang, S., Xing, L., Liu, H., et al. (2012). OCT assessment of allograft vasculopathy in heart transplant recipients. JCMG Elsevier Incorporation, 5(6), 662–3.
  9.Authors/Task Force Members, Windecker, S., Kolh, P., Alfonso, F., Collet, J.-P., Cremer, J., et al. (2014). ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal, 35(37), 2541–619. Oct 1.CrossRef
  10.Onuma, Y., Serruys, P. W., Perkins, L. E. L., Okamura, T., Gonzalo, N., Garcia-Garcia, H. M., et al. (2010). Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation, 122(22), 2288–300.CrossRef PubMed
  11.Vert, M. (2009). Bioabsorbable polymers in medicine: an overview. EuroIntervention, 15(5), F9–F14.CrossRef
  12.Serruys, P. W., Ormiston, J. A., Onuma, Y., Regar, E., Gonzalo, N., Garcia-Garcia, H. M., et al. (2009). A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. The Lancet, 373(9667), 897–910 Elsevier Ltd.CrossRef
  13.Ribichini, F., Pighi, M., Faggian, G., Vassanelli, C. Bioresorbable vascular scaffolds in cardiac allograft vasculopathy: a new therapeutic option. AJM, 126(11):e11–4.
  14.Lipinski, M. J., Escarcega, R. O., Lhermusier, T., & Waksman, R. (2014). The effects of novel, bioresorbable scaffolds on coronary vascular pathophysiology. Journal of Cardiovascular Translational Research, 7(4), 413–25.CrossRef PubMed
  15.Capranzano, P., Testa, L., Tamburino, C., Capodanno, D., Biondi-Zoccai, G., Longo, G., et al. (2014). Technical features of Absorb(TM) BVS implantation in the IT-DISAPPEARS registry. Giornale Italiano di Cardiologia (Rome), 15(9), 475–81.
  16.Prati, F., Regar, E., Mintz, G. S., Arbustini, E., Di Mario, C., Jang, I. K., et al. (2010). Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. European Heart Journal, 31(4), 401–15.CrossRef PubMed
  17.Tearney, G. J., Regar, E., Akasaka, T., Adriaenssens, T., Barlis, P., Bezerra, H. G., et al. (2012). Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies. JAC, 59(12), 1058–72. Elsevier Inc.CrossRef
  18.Tuzcu, E. M., Kapadia, S. R., Tutar, E., Ziada, K. M., Hobbs, R. E., McCarthy, P. M., et al. (2001). High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation, 103(22), 2705–10.CrossRef PubMed
  19.Stone, G. W., Maehara, A., Lansky, A. J., de Bruyne, B., Cristea, E., Mintz, G. S., et al. (2011). A prospective natural-history study of coronary atherosclerosis. The New England Journal of Medicine, 364(3), 226–35.CrossRef PubMed
  20.Mehran, R., Aymong, E. D., Nikolsky, E., Lasic, Z., Iakovou, I., Fahy, M., et al. (2004). A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. Journal of the American Chemical Society, 44(7), 1393–9.
  21.Weis, M., & von Scheidt, W. (2000). Coronary artery disease in the transplanted heart. Annual Review of Medicine, 51(1), 81–100.CrossRef PubMed
  22.Lund, L. H., Edwards, L. B., Kucheryavaya, A. Y., Benden, C., Christie, J. D., Dipchand, A. I., et al. (2014). The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report—2014; focus theme: retransplantation. HEALUN, 33(10), 996–1008. Elsevier.
  23.Simpson, L., Lee, E. K., Hott, B. J., Vega, D. J., & Book, W. M. (2005). Long-term results of angioplasty vs stenting in cardiac transplant recipients with allograft vasculopathy. The Journal of Heart and Lung Transplantation, 24(9), 1211–7.CrossRef PubMed
  24.Schmauss, D., & Weis, M. (2008). Cardiac allograft vasculopathy: recent developments. Circulation [Internet], 117(16), 2131–41. Available from: http://​eutils.​ncbi.​nlm.​nih.​gov/​entrez/​eutils/​elink.​fcgi?​dbfrom=​pubmed&​id=​18427143&​retmode=​ref&​cmd=​prlinks .CrossRef
  25.Benza, R. L., Zoghbi, G. J., Tallaj, J., Brown, R., Kirklin, J. K., Hubbard, M., et al. (2004). Palliation of allograft vasculopathy with transluminal angioplasty: a decade of experience. Journal of the American Chemical Society, 43(11), 1973–81.
  26.Bader, F. M., Kfoury, A. G., Gilbert, E. M., Barry, W. H., Humayun, N., Hagan, M. E., et al. (2006). Percutaneous coronary interventions with stents in cardiac transplant recipients. The Journal of Heart and Lung Transplantation, 25(3), 298–301. Elsevier.CrossRef PubMed
  27.Berry, C., van’t Veer, M., Witt, N., Kala, P., Bocek, O., Pyxaras, S. A., et al. (2013). VERIFY (VERification of Instantaneous Wave-Free Ratio and Fractional Flow Reserve for the Assessment of Coronary Artery Stenosis Severity in EverydaY Practice): a multicenter study in consecutive patients. Journal of the American College of Cardiology, 61(13), 1421–7.CrossRef PubMed
  28.Gomez-Lara, J., Brugaletta, S., Farooq, V., Onuma, Y., Diletti, R., Windecker, S., et al. (2011). Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography. JACC. Cardiovascular Interventions, 4(12), 1271–80.CrossRef PubMed
  29.Ormiston, J. A., Serruys, P. W., Regar, E., Dudek, D., Thuesen, L., Webster, M. W., et al. (2008). A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet, 371(9616), 899–907.CrossRef PubMed
  30.Ormiston, J. A., Serruys, P. W., Onuma, Y., van Geuns, R. J., de Bruyne, B., Dudek, D., et al. (2012). First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Circulation: Cardiovascular Interventions, 5(5), 620–32. Lippincott Williams & Wilkins.
  31.Brugaletta, S., Radu, M. D., Garcia-Garcia, H. M., Heo, J. H., Farooq, V., Girasis, C., et al. (2012). Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis, 221(1), 106–12. Elsevier.CrossRef PubMed
  
• 作者单位：Michele Pighi (1)
  Fabrizio Tomai (2)
  Alessandro Petrolini (2)
  Leonardo de Luca (2)
  Giuseppe Tarantini (3)
  Alberto Barioli (3)
  Paola Colombo (4)
  Silvio Klugmann (4)
  Marco Ferlini (5)
  Maurizio Ferrario Ormezzano (5)
  Bruno Loi (6)
  Paolo Calabrò (7)
  Renato Maria Bianchi (7)
  Giuseppe Faggian (8)
  Alberto Forni (8)
  Corrado Vassanelli (1)
  Marco Valgimigli (9)
  Flavio Ribichini (1)
  
  1. Department of Medicine, University of Verona, Piazzale Aristide Stefani n 1, 37126, Verona, Italy
  2. Department of Cardiovascular Sciences, European Hospital, Via Portuense, 700, 00149, Rome, Italy
  3. Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy
  4. Department of Cardiology and Cardiac Surgery, A. De Gasperis Niguarda Ca’ Granda Hospital, Milan, Italy
  5. Department of Cardiovascular Sciences, IRCCS Foundation, Policlinico San Matteo, Pavia, Italy
  6. Department of Cardiovascular Sciences, Brotzu Hospital, Cagliari, Italy
  7. Cardio-thoracic and Respiratory Sciences Department, Second University of Naples, Monaldi Hospital, A.O.R.N. dei Colli, Naples, Italy
  8. Department of Cardiac Surgery, University of Verona, Piazzale Aristide Stefani n 1, 37126, Verona, Italy
  9. Cardialysis, Rotterdam, The Netherlands
  
• 刊物主题：Cardiology; Human Genetics; Biomedical Engineering; Biomedicine general; Medicine/Public Health, general;
• 出版者：Springer US
• ISSN：1937-5395

文摘

Cardiac allograft vasculopathy (CAV) is a form of accelerated atherosclerosis, which represents the leading cause of late morbidity and mortality after heart transplantation. The recent bioresorbable vascular scaffold (BVS) technology represents a potential novel therapeutic tool, in the context of CAV, by allowing transient scaffolding and concomitant vessel healing. Eligible subjects will be treated by using the Absorb Everolimus-Eluting BVS (Abbott Vascular, Santa Clara, CA, USA), and evaluated at pre-determined time points, up to 3 years since the index procedure. Both clinical and imaging data will be collected in dedicated case report forms (CRF). All imaging data will be analyzed in an independent core laboratory. The primary aim of the study is to evaluate the angiographic performance at 1 year of second-generation Absorb BVS, in heart transplant recipients affected by CAV.